Could a popular Weight-Loss drug help people with rare genetic obesity?
NCT ID NCT06380426
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 175 adolescents and adults with monogenic obesity—a rare form caused by specific gene changes—who are taking semaglutide (Ozempic/Wegovy). Researchers will track weight and BMI changes over 4 years to see if the drug helps control weight in this group. The goal is to provide real-world evidence for using semaglutide in people who often don't respond well to diet, exercise, or surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- semaglutide (Ozempic/Wegovy)
- What this could lead to
- If successful, this could show that semaglutide is an effective treatment for managing weight in people with rare genetic obesity.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It is also small (175 people) and focused on a rare condition, so findings may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 175 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2024
- Expected to finish
-
Nov 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients (≥12 years) with monogenic obesity due to any variant regardless of pathogenicity classification and already treated or with the physician's decision to initiate treatment with Semaglutide in the standard care. Patients under legal protection and State Medical Assistance (AME) will be included.
- Ages
-
12 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients (≥12 years) having already initiated a treatment with SEMAGLUTIDE (regardless of the context: early access, routine care, self-financing, or exceptional reimbursement) or with a physician's decision to initiate treatment in the standard care. All patients having initiated treatment will be proposed to participate, including those having already stopped the treatment at the time of study initiation. * Confirmation of monogenic obesity, as practiced in clinical routine, regardless of current classification (i.e., pathogenic, likely pathogenic, variant of uncertain significance \[VUS\], or benign) in a gene with leptin-melanocortin pathway described in PNDS (https://www.has-sante.fr/jcms/p\_3280217/fr/generique-obesites-de-causes-rares). ) For patients with VUS or benign variants, inclusion is conditional on the availability of a polygenic risk score (PRS) * Patients duly informed and not objecting to participate in the study. For patients ≥12 years \<18 years Parents duly informed and not objecting that their child taking part in the study * Patients affiliated to a social security scheme or State Medical Assistance (AME). Exclusion Criteria: * Pregnant and breastfeeding women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Monogenic obesity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU Pitié Salpêtrière - APHP
RECRUITINGParis, 75013, France
-
Centre de référence Syndrome de Prader-Willi et autres obésités avec troubles du comportement alimentaire (PRADORT). Service de Nutrition, GH Pitié-Salpêtrière, APHP
NOT_YET_RECRUITINGParis, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.